Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma

Publisher： Karger

E-ISSN： 1664-5553|5|4|235-244

ISSN： 2235-1795

Source： Liver Cancer, Vol.5, Iss.4, 2016-09, pp. : 235-244

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib

By  

Liver Cancer, Vol. 6, Iss. 3, 2017-03 ,pp. : 177-184

Karger

Access to resources Recommend Favorite

Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors

By  

Digestive Diseases, Vol. 34, Iss. 6, 2016-10 ,pp. : 714-730

Karger

Access to resources Recommend Favorite

Systemic Treatment of Hepatocellular Carcinoma

By  

Digestive Diseases, Vol. 19, Iss. 4, 2002-03 ,pp. : 311-323

Karger

Access to resources Recommend Favorite

New Paradigm for Management of Hepatocellular Carcinoma by Imaging

By  

Liver Cancer, Vol. 1, Iss. 2, 2012-09 ,pp. : 94-109

Karger

Access to resources Recommend Favorite

Treatment of Hepatocellular Carcinoma in the Community: Disparities in Standard Therapy

By  

Liver Cancer, Vol. 4, Iss. 1, 2015-02 ,pp. : 70-83

Karger

Access to resources Recommend Favorite